Blog

Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial
Lång U, Metsälä J, Ramsay H, Boland F, Heikkilä K, Pulakka A, Lawlor A, O’Connor K, Veijola J, Kajantie E, Healy C, Kelleher I. Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial. Am J Psychiatry. 2025 Nov 5:appiajp20240958. doi: 10.1176/appi.ajp.20240958. Epub ahead of print. PMID: 41190738.
  • Study Overview: Large population-based analysis of >56,000 Finnish adolescents in mental health services who received antibiotics.
  • Key Finding: Doxycycline use linked to 30–35% lower risk of developing schizophrenia in adulthood vs. other antibiotics.
  • Mechanism: May reduce brain inflammation and moderate excessive synaptic pruning, a process tied to schizophrenia.
  • Implications: Suggests repurposing doxycycline as potential early preventive intervention for high-risk youth; needs clinical trials to confirm.
Autism Spectrum Disorders and Lyme Disease: Exploring Shared Neuro-Inflammatory and Immune Pathways
DASHORE, Jodie A. et al. Autism Spectrum Disorders and Lyme Disease: Exploring Shared Neuro-Inflammatory and Immune Pathways. Medical Research Archives, [S.l.], v. 13, n. 11, nov. 2025. ISSN 2375-1924. doi: https://doi.org/10.18103/mra.v13i11.7019.

  • Examines Lyme disease and co-infections as infectious drivers of neuroinflammation overlapping with autism spectrum disorder.

  • Reports a cohort of 1,722 children with treatment-resistant ASD and PANS/PANDAS who met clinical criteria for chronic inflammatory response syndrome (CIRS).

  • Describes improvements in cognition, motor skills, and gastrointestinal function following CIRS-directed therapies.

  • Identifies a subset of children in tick-endemic regions with Lyme-specific clinical features, diagnosed clinically using CDC criteria.

  • Notes immune mechanisms including blood–brain barrier disruption, immune imbalance, mitochondrial dysfunction, and microglial priming.

  • Highlights diagnostic challenges due to limited sensitivity of conventional serologic testing in early or chronic disease.

Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome

Weinstock LB, Afrin LB, Reiersen AM, Brook J, Blitshteyn S, Ehrlich G, Schofield JR, Kinsella L, Kaufman D, Dempsey T, Molderings GJ. Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome. Brain, Behavior, & Immunity – Health. 2025;48:101048.doi:10.1016/j.bbih.2025.101048

  • MCAS is a common inflammatory disease characterized by mast cell dysregulation.
  • 19 neurologic and 14 psychologic disorders were significantly increased in MCAS subjects.
  • Chemical mediators, genetic predisposition, and life experiences could determine which disorders occur or worsen.